Created at Source Raw Value Validated value
June 25, 2024, noon usa

* if the patient uses \> 5 lo2/min at time of recruitment * known intolerance/allergy to azithromycin or hydroxychloroquine or hypersensitivity to quinine or 4-aminoquinolinderivates * pregnancy * breastfeeding * neurogenic hearing loss * psoriasis * retinopathy * maculopathy * changes in vision field * severe liver disease other than amoebiases * severe gastrointestinal, neurological or haematological disorders * egfr \< 45 ml/min/1.73m2 * clinically significant cardiac conduction disorders/arrhythmias or prolonged qtc interval * myasthenia gravis * uses digoxin * glucose-6-phosphate dehydrogenase deficiency * porphyria * hypoglycemia at any time since hospitalization * severe mental illness which significantly impedes cooperation * severe linguistic problems that significantly impedes cooperation * treatment with sickle alkaloids

* if the patient uses \> 5 lo2/min at time of recruitment * known intolerance/allergy to azithromycin or hydroxychloroquine or hypersensitivity to quinine or 4-aminoquinolinderivates * pregnancy * breastfeeding * neurogenic hearing loss * psoriasis * retinopathy * maculopathy * changes in vision field * severe liver disease other than amoebiases * severe gastrointestinal, neurological or haematological disorders * egfr \< 45 ml/min/1.73m2 * clinically significant cardiac conduction disorders/arrhythmias or prolonged qtc interval * myasthenia gravis * uses digoxin * glucose-6-phosphate dehydrogenase deficiency * porphyria * hypoglycemia at any time since hospitalization * severe mental illness which significantly impedes cooperation * severe linguistic problems that significantly impedes cooperation * treatment with sickle alkaloids

July 1, 2021, 2:30 a.m. usa

- if the patient uses > 5 lo2/min at time of recruitment - known intolerance/allergy to azithromycin or hydroxychloroquine or hypersensitivity to quinine or 4-aminoquinolinderivates - pregnancy - breastfeeding - neurogenic hearing loss - psoriasis - retinopathy - maculopathy - changes in vision field - severe liver disease other than amoebiases - severe gastrointestinal, neurological or haematological disorders - egfr < 45 ml/min/1.73m2 - clinically significant cardiac conduction disorders/arrhythmias or prolonged qtc interval - myasthenia gravis - uses digoxin - glucose-6-phosphate dehydrogenase deficiency - porphyria - hypoglycemia at any time since hospitalization - severe mental illness which significantly impedes cooperation - severe linguistic problems that significantly impedes cooperation - treatment with sickle alkaloids

- if the patient uses > 5 lo2/min at time of recruitment - known intolerance/allergy to azithromycin or hydroxychloroquine or hypersensitivity to quinine or 4-aminoquinolinderivates - pregnancy - breastfeeding - neurogenic hearing loss - psoriasis - retinopathy - maculopathy - changes in vision field - severe liver disease other than amoebiases - severe gastrointestinal, neurological or haematological disorders - egfr < 45 ml/min/1.73m2 - clinically significant cardiac conduction disorders/arrhythmias or prolonged qtc interval - myasthenia gravis - uses digoxin - glucose-6-phosphate dehydrogenase deficiency - porphyria - hypoglycemia at any time since hospitalization - severe mental illness which significantly impedes cooperation - severe linguistic problems that significantly impedes cooperation - treatment with sickle alkaloids

Oct. 26, 2020, 11:31 p.m. usa

- if the patient uses > 5 lo2/min at time of recruitment - known intolerance/allergy to azithromycin or hydroxychloroquine or hypersensitivity to quinine or 4-aminoquinolinderivates - pregnancy - breatfeeding - neurogenic hearing loss - psoriasis - retinopathy - maculopathy - changes in vision field - severe liver disease other than amoebiases - severe gastrointestinal, neurological or haematological disorders - egfr < 45 ml/min/1.73m2 - clinically significant cardiac conduction disorders/arrhytmias or prolonged qtc interval - myasthenia gravis - uses digoxin - glucose-6-phosphate dehydrogenase defiency - porphyria - hypoglycemia at any time since hospitalization - severe mental illness which significantly impedes cooperation - severe linguistic problems that significantly impedes cooperation - treatment with sickle alkaloids

- if the patient uses > 5 lo2/min at time of recruitment - known intolerance/allergy to azithromycin or hydroxychloroquine or hypersensitivity to quinine or 4-aminoquinolinderivates - pregnancy - breatfeeding - neurogenic hearing loss - psoriasis - retinopathy - maculopathy - changes in vision field - severe liver disease other than amoebiases - severe gastrointestinal, neurological or haematological disorders - egfr < 45 ml/min/1.73m2 - clinically significant cardiac conduction disorders/arrhytmias or prolonged qtc interval - myasthenia gravis - uses digoxin - glucose-6-phosphate dehydrogenase defiency - porphyria - hypoglycemia at any time since hospitalization - severe mental illness which significantly impedes cooperation - severe linguistic problems that significantly impedes cooperation - treatment with sickle alkaloids